246 related articles for article (PubMed ID: 8265104)
21. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
22. [Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)].
Olivier C; Carballido J; Lao AH; Gimeno A; Martín C; Renjifo D; Ondina LM; Manzano L; Alvarez-Mon M
Actas Urol Esp; 1995 Jan; 19(1):16-26. PubMed ID: 7717154
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
26. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
Huland E; Heinzer H; Huland H
Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
[TBL] [Abstract][Full Text] [Related]
29. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
Ravaud A; Négrier S; Cany L; Merrouche Y; Le Guillou M; Blay JY; Clavel M; Gaston R; Oskam R; Philip T
Br J Cancer; 1994 Jun; 69(6):1111-4. PubMed ID: 8198979
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy in the management of metastatic renal carcinoma].
Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
[TBL] [Abstract][Full Text] [Related]
32. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
Finck-Seelen ; Lampert R; Brandt L
Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
[TBL] [Abstract][Full Text] [Related]
33. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
34. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
35. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
Bukowski RM
Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
[TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF
Cancer; 2009 May; 115(10 Suppl):2298-305. PubMed ID: 19402060
[TBL] [Abstract][Full Text] [Related]
39. Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma.
Thiounn N; Mathiot C; Dorval T; Flam TA; Tartour E; Mosseri V; Zerbib M; Fridman WH; Debre B
Br J Urol; 1995 May; 75(5):586-9. PubMed ID: 7613793
[TBL] [Abstract][Full Text] [Related]
40. [Immunotherapy of metastatic renal cell carcinoma: report of 28 cases].
Wang HJ; Wang H; Li HZ; Shi BB; Song ZL
Zhonghua Wai Ke Za Zhi; 2004 Feb; 42(4):205-6. PubMed ID: 15062035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]